1392 unknown. 1392 Phase 2, 204 Phase 1, 99 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1392 | Unknown 1392 |
| Phase 1 | 204 | Unknown 204 |
| Phase 3 | 99 | Unknown 99 |
Follow Digestive System Neoplasms: new trials by email Literature Review of Digestive System Neoplasms trials Research Report on Digestive System Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Node-Sparing Short-Course Radiation With CAPOX and Sintilimab for MSS Locally Advanced Colon Cancer: A Randomized, Prospective, Multicenter Study Node-Sparing Short-Course Radiotherapy Combined with CAPOX and Sintilimab, CAPOX Chemotherapy - Microsatellite Stable (MSS) Colon Cancer, Locally Advanced Colon Cancer | Phase 2 | Unknown | Sir Run Run Shaw Hospital | 140 | 2024-10-01 | 2024-09-19 |
| BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma BTLA inhibitor (JS004), Toripalimab, Paclitaxel, Cisplatin - Esophageal Squamous Cell Carcinoma | Phase 2 | Unknown | Henan Provincial People's Hospital | 20 | 2024-09-30 | 2024-09-19 |
| A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation Camrelizumab, Apatinib - Hepatocellular Carcinoma | Phase 2 | Unknown | Zhujiang Hospital | 38 | 2024-08-26 | 2024-08-09 |
| Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study FOLFOXIRI Protocol - Neoplasm Malignant, Colon Cancer Stage 4 | Phase 2 | Unknown | Al-Azhar University | 60 | 2024-08-17 | 2024-08-28 |
| Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer Irinotecan Liposome, Bevacizumab - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Unknown | West China Hospital | 20 | 2024-08-09 | 2024-08-09 |
| A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis Sintilimab, Ramucirumab, SOX/XELOX - Stomach Neoplasms | Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 39 | 2024-08-01 | 2024-08-28 |
| Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma Cryoablation, PD-1 antibody and bevacizumab - Carcinoma, Hepatocellular | Phase 2 | Unknown | Shanghai Zhongshan Hospital | 36 | 2024-07-31 | 2024-07-31 |
| Prospective Phase II Study on Continuous Circumferential Reinforcement of Laparoscopic Rectal Anastomosis to Prevent Complications Continuous Circumferential Reinforcement of the Anastomotic - Colorectal Cancer, Anastomotic Leakage | Phase 2 | Unknown | ZHI-ZHONG PAN | 208 | 2024-07-20 | 2024-07-11 |
| HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular Carcinoma HAIC（Mitoxantrone+Raltitrexed）、anlotinib、TQB2450 - Hepatocellular Carcinoma | Phase 2 | Unknown | Fudan University | 42 | 2024-07-20 | 2024-06-26 |
| MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer PD-1 monoclonal antibody consolidation therapy - Esophageal Cancer | Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 102 | 2024-07-16 | 2024-08-06 |
| Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC. Adebrelimab, Apatinib, Investigator chosen chemotherapy (ICC) - Esophageal Cancer | Phase 2 | Unknown | The First Affiliated Hospital of Henan University of Science and Technology | 54 | 2024-07-15 | 2024-06-18 |
| Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer Trilaciclib Injection [Cosela], Placebo - Esophageal Cancer | Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 60 | 2024-07-09 | 2024-08-26 |
| Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes Therapy in Patients With Hepatocellular Carcinoma Autologous Tumor-infiltrating Lymphocytes - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Unknown | Beijing 302 Hospital | 20 | 2024-07-01 | 2024-08-13 |
| First-Line Treatment Induced With mFOLFOX6 and HLX04 Regimen, Following Combined With Serplulimab in MSS Initially Unresectable Metastatic Colorectal Cancer mfolfox6 and hlx04 regimen and Serplulimab, mfolfox6 and hlx04 regimen - Efficacy, Self, Safety Issues | Phase 2 | Unknown | Sir Run Run Shaw Hospital | 72 | 2024-07-01 | 2024-07-09 |
| HAIC Combined With Adebrelimab Plus Apatinib as the First-line Treatment for HCC in BCLC Stage C: An Open-label, Single-arm, Phase II Study Hepatic arterial infusion chemotherapy(HAIC) combined with adebrelimab plus apatinib - Hepatocellular Carcinoma | Phase 2 | Unknown | Sun Yat-sen University | 33 | 2024-06-19 | 2024-07-01 |
| Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer Adebrelimab, Oxaliplatin 100 MG, Irinotecan liposome - Pancreatic Cancer | Phase 2 | Unknown | Fudan University | 87 | 2024-06-05 | 2024-08-09 |
| Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer Liposomal irinotecan, Bevacizumab - Colorectal Cancer | Phase 1 / Phase 2 | Unknown | Sun Yat-sen University | 74 | 2024-06-05 | 2024-05-30 |
| Multimodal Rehabilitation on Gastric Adenocarcinoma Patients Following Radical D2 Gastrectomy Standard SOX/XELOX adjuvant chemotherapy plus multimodal rehabilitation - Gastric Cancer | Phase 2 | Unknown | Zhejiang Cancer Hospital | 138 | 2024-06-01 | 2024-05-17 |
| Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab mFOLFOX6 regimen + bevacizumab + PD-1 monoclonal antibody - Metastatic Colorectal Cancer, MSS | Phase 2 | Unknown | Zhangfa Song | 36 | 2024-06-01 | 2024-05-16 |
| Phase II Study of Liposomal Irinotecan for Advanced Refractory Gastric Cancer Liposomal Irinotecan Hydrochloride - Gastric Cancer | Phase 2 | Unknown | Zhejiang Cancer Hospital | 50 | 2024-05-27 | 2024-05-31 |
Showing 20 of 1392. Sign in to see all of them.
Colorectal Neoplasms (324) · Stomach Neoplasms (285) · Carcinoma, Hepatocellular (241) · Pancreatic Neoplasms (163) · Rectal Neoplasms (123) · Esophageal Neoplasms (121) · Esophageal Squamous Cell Carcinoma (102) · Colonic Neoplasms (90) · Liver Neoplasms (53) · Neoplasm Metastasis (48) · Biliary Tract Neoplasms (40) · Neoplasms (31) · Breast Neoplasms (25) · Gastrointestinal Neoplasms (21) · Carcinoma, Non-Small-Cell Lung (20)
Digestive System Diseases (1390) · Neoplasms by Site (1383) · Neoplasms (1361) · Gastrointestinal Diseases (940) · Gastrointestinal Neoplasms (922) · Intestinal Diseases (480) · Intestinal Neoplasms (475) · Rectal Diseases (423) · Neoplasms by Histologic Type (410) · Neoplasms, Glandular and Epithelial (390) · Colonic Diseases (387) · Carcinoma (370) · Stomach Diseases (286) · Liver Diseases (273)
Oxaliplatin (159) · Capecitabine (124) · Fluorouracil (111) · Irinotecan (89) · Leucovorin (72) · S 1 (combination) (70) · Cisplatin (69) · apatinib (69) · Paclitaxel (66) · Bevacizumab (64) · sintilimab (62) · Gemcitabine (60) · camrelizumab (56) · Radiotherapy (51) · Cetuximab (49)
Fudan University (73) · Sun Yat-sen University (63) · Tianjin Medical University Cancer Institute and Hospital (38) · Chinese Academy of Medical Sciences (26) · Shanghai Zhongshan Hospital (25) · Zhejiang Cancer Hospital (24) · Peking University (19) · National Cancer Center, Korea (18) · Chinese PLA General Hospital (17) · Second Affiliated Hospital, Zhejiang University, School of Medicine (17) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (16) · GERCOR - Multidisciplinary Oncology Cooperative Group (15) · Samsung Medical Center (15) · The First Affiliated Hospital of Zhengzhou University (15) · The First Affiliated Hospital with Nanjing Medical University (15)
China (743) · South Korea (98) · United States (87) · Taiwan (35) · France (34) · United Kingdom (32) · Japan (29) · Netherlands (27) · Germany (26) · Italy (26) · Spain (19) · Singapore (15) · Canada (13) · Brazil (12) · Australia (11)
Feng Wang (5) · Lin Shen, MD (5) · Lin Shen, Professor (5) · Wei Peng Yong, MRCP, MB ChB (5) · Christophe Louvet, MD, PhD (3) · Fuxiang Zhou, M.D. (3) · Gang Jin, Doctor (3) · Gao-Jun Teng, MD (3) · Haitao Zhao, MD (3) · Hui-Ju Ch'ang, M.D. (3) · Jian Zhou (3) · Jingdong Zhang (3) · Kun Huei Yeh, Ph.D. (3) · Lin Yang, Ph.D. (3) · Ruihua Xu, MD, PhD (3)
PMID 30642373, PMID 35623069, PMID 12049862, PMID 12540794, PMID 15273542, PMID 20516446, PMID 23547081, PMID 25447852, PMID 25514302, PMID 26313683, PMID 26755520, PMID 26884585, PMID 27480145, PMID 28434648, PMID 30348638, PMID 32306237, PMID 34725214, PMID 35219300, PMID 36657089, PMID 37981041, PMID 38421211, PMID 39863139, PMID 41379261, PMID 10089184, PMID 10091726, PMID 10400410, PMID 10615932, PMID 10744089, PMID 11091234, PMID 11223832, PMID 11247898, PMID 11248153, PMID 11251976, PMID 11289756, PMID 11413430, PMID 11419162, PMID 11574279, PMID 11712875, PMID 11754382, PMID 11813623, PMID 11896099, PMID 11981766, PMID 12091661, PMID 12187070, PMID 12196368, PMID 12378346, PMID 1334988, PMID 14525967, PMID 14578723, PMID 14759776
2016 (5), 2018 (5), P30CA015083 (4), 2009 (3), 2015 (3), 2017 (3), 2019 (3), 2008 (2), 2005 (1), 2014 (1), M01RR000096 (1), P20CA252732 (1), P30CA168524 (1), R44CA256984 (1), U10CA031946 (1)